GILEAD SCIENCES, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
GILEAD SCIENCES, INC. (GILD) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $245.00 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2024-11-12
- GILEAD SCIENCES, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-09-30 was $77.00M, a 67.39% increase year-over-year.
- GILEAD SCIENCES, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-06-30 was $33.00M, a 135.71% increase year-over-year.
- GILEAD SCIENCES, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-03-31 was $135.00M, a 48.35% increase year-over-year.
- GILEAD SCIENCES, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2022-09-30 was $46.00M.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month |
|---|---|---|---|
| 2023-09-30 | $77.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $110.00M derived: sum of 2 quarters · filed 2024-11-12 | $245.00M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $33.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $168.00M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $135.00M 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | $46.00M 10-Q · filed 2023-11-07 | $60.00M derived: sum of 2 quarters · filed 2023-11-07 | $151.00M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $14.00M 10-Q · filed 2023-08-04 | $104.00M 10-Q · filed 2023-08-04 | |
| 2022-03-31 | $91.00M 10-Q · filed 2023-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |